The HIV antiretroviral drug efavirenz has LSD-like properties

Neuropsychopharmacology

Volumn 38, Issue 12, 2013, Pages 2373-2384

  Gatch, Michael B ^a   Kozlenkov, Alexey ^b   Huang, Ren Qi ^a   Yang, Wenjuan ^c   Nguyen, Jacques D ^a   González Maeso, Javier ^b   Rice, Kenner C ^d   France, Charles P ^c   Dillon, Glenn H ^a   Forster, Michael J ^a   Schetz, John A ^a,e  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e University of North Texas Health Science Center   (United States)

Author keywords

adverse neuropsychiatric events; AIDS; hallucinogen; side effects

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; DOPAMINE TRANSPORTER; EFAVIRENZ; LYSERGIDE; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; DISCRIMINATIVE STIMULUS; HALLUCINATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LOCOMOTION; MALE; NIGHTMARE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-HIV AGENTS; BEHAVIOR, ANIMAL; BENZOXAZINES; CONDITIONING (PSYCHOLOGY); DISCRIMINATION (PSYCHOLOGY); HALLUCINOGENS; LYSERGIC ACID DIETHYLAMIDE; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, CELL SURFACE; SEROTONIN 5-HT2 RECEPTOR AGONISTS;

EID: 84888343795     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.135     Document Type: Article

References (43)

1. Adams LM, Geyer MA (1982). LSD-induced alterations of locomotor patterns and exploration in rats. Psychopharmacology (Berl) 77: 179-185. (Pubitemid 12038119)
2. Adams LM, Geyer MA (1985). Effects of DOM and DMT in a proposed animal model of hallucinogenic activity. Prog Neuropsychopharmacol Biol Psychiatry 9: 121-132. (Pubitemid 15089220)
3. Anthony JC, Warner LA, Kessler RC (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the national comorbidity survey. Exp Clin Psychopharmacol 2: 244-268.
4. Arribas JR (2003). Efavirenz: enhancing the gold standard. Int J STD AIDS 14(Suppl 1): 6-14. (Pubitemid 37352575)
5. Best BM, Goicoechea M (2008). Efavirenz-still first-line king Expert Opin Drug Metab Toxicol 4: 965-972.
6. Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB et al CHARTER Group (2011). Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother 66: 354-357.
7. Brown JM, Hanson GR, Fleckenstein AE (2001). Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther 296: 762-767. (Pubitemid 32187345)
8. Central Intelligence Agency (CIA) World Fact Book (2009): Country Comparisons-HIV/AIDS-adult prevalence rate. Data from 2007 estimates. Available at: https://www.cia.gov/library/publications/the-world-factbook/rankorder/ 2155rank.html.
9. Cespedes MS, Aberg JA (2006). Neuropsychiatric complications of antiretroviral therapy. Drug Saf 29: 865-874. (Pubitemid 44511587)
10. Cesura AM, Bertocci B, Da Prada M (1990). Binding of [3H] dihydrotetrabenazine and [125I]azidoiodoketanserin photoaffinity labeling of the monoamine transporter of platelet 5-HT organelles. Eur J Pharmacol 1990 186: 95-104. (Pubitemid 20277550)
11. Chen CY, Storr CL, Anthony JC (2009). Early-onset drug use and risk for drug dependence problems. Addict Behav 34: 319-322.
12. Cunningham CL, Gremel CM, Groblewski PA (2006). Druginduced conditioned place preference and aversion in mice. Nat Protoc 1: 1662-1670. (Pubitemid 46773287)
13. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK;Panel on Clinical Practices for Treatment of HIV (2002) Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 137: 381-433.
14. Ericksen SS, Cummings DF, Weinstein H, Schetz JA (2009). Ligand selectivity of D2 dopamine receptors is modulated by changes in local dynamics produced by sodium binding. J Pharm Exp Ther 328: 40-54.
15. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E (1996). Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 93: 5166-5171. (Pubitemid 26162890)
16. Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC et al (2006). Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav 83: 122-129.
17. Fantegrossi WE, Murnane KS, Reissig CJ (2008). The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75: 17-33. (Pubitemid 350235393)
18. Fiorella D, Rabin RA, Winter JC (1995). The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology (Berl) 121: 347-356.
19. Gatch MB, Rutledge M, Carbonaro T, Forster MJ (2009). Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats. Psychopharmacology 204: 715-724.
20. Glennon RA, Titeler M, McKenney JD (1984). Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35: 2505-2511. (Pubitemid 15212191)
21. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH (2009). Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther 329: 827-837.
22. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R et al (2007). Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53: 439-452. (Pubitemid 46161267)
23. Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF et al (2008). Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452: 93-97. (Pubitemid 351355090)
24. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA et al (2004). Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment. N Engl J Med 350: 1850-1861. (Pubitemid 38917251)
25. Grailhe R, Waeber C, Dulawa SC, Hornung JP, Zhuang X, Brunner D et al (1999). Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor. Neuron 22: 581-591. (Pubitemid 29159856)
26. Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J et al (2005). Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 41: 1648-1653. (Pubitemid 41691605)
27. Halberstadt AL, van der Heijden I, Ruderman MA, Risbrough VB, Powell SB (2009). 5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice (2009). Neuropsychopharmacology 34: 1958-1967.
28. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S et al (2008). International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300: 555-570.
29. Han DD, Gu HH (2006). Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6: 7.
30. Huang RQ, Singh M, Dillon GH (2010). Genistein directly inhibits NMDA receptors in mouse hippocampal neurons. Neuropharmacology 58: 1246-1251.
31. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET et al (2001). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58: 322-328. (Pubitemid 32299527)
32. Lacivita E, Paola De Giorgio P, Lee IT, Rodeheaver SI, Weiss BA, Fracasso C et al (2010). Design, synthesis, radiolabeling and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3- methoxybenzamide, a potential PET tracer for the dopamine D4 receptors. J Med Chem 53: 7344-7355.
33. Marwaha A (2008). Getting High on HIV drugs in S Africa, BBC News, 8 December 2008. Available at: http://news.bbc.co.uk/2/hi/africa/7768059.stm.
34. Meltzer HY, Fessler RG, Simonovic M, Doherty J, Fang VS (1977). Lysergic acid diethylamide: evidence for stimulation of pituitary dopamine receptors. Psychopharmacology (Berl) 54: 39-44. (Pubitemid 8170312)
35. National Research Council (2003). Guidelines for the care and use of mammals in neuroscience and behavioral research. The National Academies Press: Washington, DC.
36. Nichols DE (2004). Hallucinogens. Pharmacol Ther 101: 131-181. (Pubitemid 38167565)
37. Patel AK, Patel KK (2006). Future implications: compliance and failure with antiretroviral treatment. J Postgrad Med 52: 197-200.
38. Rossi S, Yaksh T, Bentley H, van den Brande G, Grant I, Ellis R (2006). Characterization of interference with 6 commercial delta-9-tetrahydrocannabinol immunoassays by Efavirenz (glucuronide) in urine. Clin Chem 52: 896-898.
39. Sciutto J (2009): ABC World News Report (4 May 2009) Shorten version 6 April 2009: 'No Turning Back': Teens Abuse HIV Drugs. Teens in South Africa Smoke Anti-Retroviral Drug Efavirenz for Cheap High portions archived at http://www. youtube.com/watchv=hjVtthQJnyU.
40. Sierra-Madero J, Villasis-Keever A, Méndez P, Mosqueda- Gómez JL, Torres-Escobar I, Gutiérrez-Escolano F et al (2010). Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV\+ treatment-naive subjects with CD4\+o200 cell/mm3 in Mexico. J Acquir Immune Defic Syndr 53: 582-588.
41. Vazquez E (1999). Sustiva flashbacks. Posit Aware 10: 17.
42. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897-3902. (Pubitemid 29189323)
43. Winter JC (2009). Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology (Berl) 203: 251-263.